The global left atrial appendage closure device market revenue was around US$ 1.8 billion in 2021 and is estimated to reach US$ 8.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% during the forecast period from 2022 to 2031.

Left atrial appendage (LAA) closure devices are implantable cardiac devices inserted into the left atrial appendage to prevent heart blockages and strokes for patients with blockages and atrial fibrillation. They may be implanted using minimally invasive, open, or percutaneous surgery, depending on the device. This device is implanted in the hearts of people with non-valvular atrial fibrillation to reduce the risk of thromboembolism from the left atrial appendage (LAA).

Factors Influencing Market Growth

- Rise in the approval of atrial intervention products, an increase in the prevalence of heart attacks and atrial fibrillation, diseases linked to hypertension, and disturbed lifestyle habits like smoking boost market growth.

- Enhanced awareness activities in unexplored markets offer a variety of opportunities for market growth. These elements are projected to fuel the market expansion.

- The availability of alternatives and the high price of left atrial appendage atrial closure devices may hamper the market growth.

Study of the COVID-19 Pandemic

The COVID-19 pandemic had a negative impact on the market. Due to the lockdown enacted by the government, several manufacturers halted their operations, and the supply chain slowed down. Healthcare workers avoided allowing patients who had Covid-infected to visit hospitals because of the fast-rising number of infected patients to stop viral transmission. Additionally, a lot of private clinics were turning away patients since there was no medical personnel available to treat them. This aspect also hindered market expansion during the pandemic.

Regional Insights

North America dominated the market. This is attributed due to some elements, such as the wide acceptance of sophisticated left atrial appendage closure devices, an increase in the prevalence of atrial fibrillation, and a well-established healthcare system nationwide. Adoption of innovative technology and high desire. Thus, these elements aid the market expansion in this region.

Leading Competitors

The leading competitors in the global left atrial appendage closure device market are:
- AtriCure
- Aegis Medical Group
- Lifetech Scientific Corporation
- SentreHEART
- Occlutech
- Abbott Laboratories
- Johnson & Johnson Services
- Biosense Webster
- Cardia
- Boston Scientific Corporation
- Others
Segmentation Analysis
The global left atrial appendage closure device market segmentation focuses on Product, End Use, and Region.
Segmentation based on Product
- Endocardial LAA Devices
- Epicardial LAA Devices
Segmentation based on End Use
- Hospitals
- Ambulatory Surgery Centers
- Others
Segmentation based on Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Western Europe
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- ASEAN
- Rest of Asia Pacific

- Middle East & Africa (MEA)
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA

- South America
- Brazil
- Argentina
- Rest of South America